Webinars (2020)
Apr 29, 2020 ‐ Dec 31, 2020
Sessions
New Way to Treat Brain Diseases at Home Using Noninvasive Brain Stimulation
Nov 5, 2020 5:30pm ‐ Nov 5, 2020 6:30pm
[Recorded Nov. 5, 2020]
The COVID-19 pandemic has highlighted a needs for non-invasive, remote approaches to patient care.
Learn how companies like Neuroelectrics are working to bring non-invasive brain stimulation into the home. In May, 2020, Neuroelectrics received FDA approval for a clinical trial of at-home brain stimulation therapy via telemedicine for patients with Major Depressive Disorder (MDD). An additional trial with Boston Children’s Hospital (IDE G160208) is already underway, studying the therapy for treatment-resistant epilepsy.
This nonaccredited educational webinar is provided for information only.
Speaker(s):- Ana Maiques, MBA, CEO & Co-Founder, Neuroelectrics
- Dr. Eric J. Grigsby, MD, MBA, Founder & CEO, Neurovations: A Patient Care and Innovation Company
The Path From "Big Idea" to Breakthrough
Preview Available
The Path From "Big Idea" to Breakthrough
Oct 8, 2020 4:30pm ‐ Oct 8, 2020 5:30pm
[Recorded Oct. 8, 2020]
What does it take to turn a big idea into a new therapy?
This engaging conversation with Eric Grigsby, MD, MBA, and David Caraway, MD PhD, explores the phases of breakthrough innovation and therapeutic development.
This nonaccredited educational webinar is provided for information only.
- Dr. David L. Caraway, MD, PhD, Chief Medical Officer, Nevro, Inc.
- Dr. Eric J. Grigsby, MD, MBA, Founder & CEO, Neurovations: A Patient Care and Innovation Company
Differential Target Multiplexed (DTM) Spinal Cord Stimulation (SCS): What is it and how does it work?
Preview Available
Differential Target Multiplexed (DTM) Spinal Cord Stimulation (SCS): What is it and how does it work?
Sep 10, 2020 4:30pm ‐ Sep 10, 2020 5:30pm
[Recorded Sept. 10, 2020]
A deep dive into how a hypothesis can change the way we think about SCS therapies and optimizing outcomes.
Dr. Vallejo unpacks the questions necessary to build a truer understanding of the effects of SCS and how the answers to these questions influence patient outcomes.
This nonaccredited educational webinar is provided for information only.
Recent Publications:
- Vallejo, R., Kelley, C. A., Gupta, A., Smith, W. J., Vallejo, A., & Cedeño, D. L. (2020). Modulation of neuroglial interactions using differential target multiplexed spinal cord stimulation in an animal model of neuropathic pain. Molecular Pain, 16, 1744806920918057.
- Vallejo, R., & Cedeño, D. L. (2020). The quest for neurobiological mechanisms of electrical stimulation of the spinal cord to reduce chronic neuropathic pain. Future Medicine (2020): 139-142.
- Fishman, M. A., Calodney, A., Kim, P., Slezak, J., Benyamin, R., Rehman, A., ... & Yu, C. (2020). Prospective, Multicenter Feasibility Study to Evaluate Differential Target Multiplexed Spinal Cord Stimulation Programming in Subjects With Chronic Intractable Back Pain With or Without Leg Pain. Pain Practice.
- Dr. Eric J. Grigsby, MD, MBA, Founder & CEO, Neurovations: A Patient Care and Innovation Company
- Dr. Ricardo Vallejo, MD, PhD, Co-Founder, Director of Research, Millennium Pain Center
Electrical Activation of Neural Reflexes for the Treatment of Autoimmune Diseases
Jul 16, 2020 4:30pm ‐ Jul 16, 2020 5:30pm
[Recorded July 16, 2020]
Rheumatoid arthritis (RA) is an autoimmune disease which leads to permanent joint destruction and accelerated mortality requiring lifelong immunosuppressive therapies. Activation of neuroimmune reflexes by vagal nerve stimulation (VNS) reduced disease activity in a proof-of-concept study in RA.
This nonaccredited educational webinar is provided for information only.
Speaker(s):- Dr. Eric J. Grigsby, MD, MBA, Founder & CEO, Neurovations: A Patient Care and Innovation Company
- Dr. David Chernoff, MD, Chief Medical Officer, SetPoint Medical
Are You Addressing Inclusion and Equity in Pain Management?
Preview Available
Are You Addressing Inclusion and Equity in Pain Management?
Jul 2, 2020 4:30pm ‐ Jul 2, 2020 5:30pm
[Recorded July 2, 2020]
Drs. Eric Grigsby, and Lawrence Poree held an in-depth conversation on equity and inclusion in pain management.
The conversation elucidates:
- Identifying and stopping patient bias
- Breaking down bias in the workplace
This nonaccredited educational webinar is provided for information only.
Additional resources:
- HHS Action Plan to Reduce Racial and Ethnic Health Disparities
- A Practical Guide to Implementing the National CLAS Standards: For Racial, Ethnic and Linguistic Minorities, People with Disabilities and Sexual and Gender Minorities
- Reducing Racial Health Care Disparities: A Social Psychological Analysis
- Dr. Eric J. Grigsby, MD, MBA, Founder & CEO, Neurovations: A Patient Care and Innovation Company
- Dr. Lawrence Poree, MD, PhD. MPH, Clinical Professor, Department of Anesthesia, University of California at San Francisco (UCSF)
Neuromodulation for the COVID-19 Cytokine Storm
Preview Available
Neuromodulation for the COVID-19 Cytokine Storm
May 28, 2020 4:30pm ‐ May 28, 2020 5:30pm
[Recorded May 28, 2020]
Learn:
- The potential of non-invasive Vagus Nerve Stimulation (nVNS) therapy to address COVID-19 induced cytokine storm.
- Preliminary observations and a strong scientific foundation suggest that nVNS might provide clinical benefits in patients with COVID‐19 via multiple mechanisms.
This nonaccredited educational webinar is provided for information only.
Speaker(s):- Dr. Eric J. Grigsby, MD, MBA, Founder & CEO, Neurovations: A Patient Care and Innovation Company
- Dr. Peter Staats, MD, MBA, FIPP, Chief Medical Officer, National Spine & Pain Centers
Interventional Pain Procedures, Neuromodulation, and COVID-19
Preview Available
Interventional Pain Procedures, Neuromodulation, and COVID-19
May 7, 2020 4:30pm ‐ May 7, 2020 5:30pm
[Recorded May 7, 2020]
Preparing Your Re-entry Plan
Mapping the Future of Pain Procedures with Neuromodulation and COVID-19
Eric J. Grigsby, MD, MBA and NANS Board Member, Stephanie G. Vanterpool, MD, MBA review exploring NANS’ Neuromodulation Device Algorithm for COVID-19.
Learn:
- How to classify the management of currently implanted neuromodulation devices as “elective” or “essential”
- Considerations for pump management during the pandemic
- Stages for re-entry: testing, tracing, and community health
- How to get back to a “new normal” once we resume doing procedures…. i.e. It won’t be business as usual
This guidance refers to the management of currently implanted neuromodulation devices. With rare exception, implantation of new devices is considered elective in the current COVID-19 environment.
This nonaccredited educational webinar is provided for information only.
- Dr. Eric J. Grigsby, MD, MBA, Founder & CEO, Neurovations: A Patient Care and Innovation Company
- Dr. Stephanie G. Vanterpool, MD, MBA, Director, Comprehensive Pain Services, University of Tennessee Graduate School of Medicine